Precision Diagnostics & Medicine Market by Diagnostic Testing, Diagnostics Indication, Therapeutic Products, Indication - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • 2.2.1 PRECISION DIAGNOSTICS MARKET
  • 2.2.2 PRECISION MEDICINE MARKET
  • 2.2.3 INSIGHTS FROM PRIMARY SOURCES
• 2.3 TOP-DOWN APPROACH
  • 2.3.1 PRECISION DIAGNOSTICS MARKET
  • 2.3.2 PRECISION MEDICINE MARKET
• 2.4 GROWTH FORECAST MODEL
• 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
• 4.2 PRECISION MEDICINE MARKET OVERVIEW
• 4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023
• 4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029
• 4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023
• 4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023
• 4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029
• 4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies
    • 5.2.1.2 Rise in direct-to-consumer testing
    • 5.2.1.3 Growing integration of artificial intelligence and machine learning
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of precision healthcare
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Expanding applications of precision healthcare
    • 5.2.3.2 Growing adoption of wearable devices
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complex regulatory approval landscape
    • 5.2.4.2 Big data management and integration issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 PRECISION DIAGNOSTICS MARKET
  • 5.5.2 PRECISION MEDICINE MARKET
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PRECISION DIAGNOSTICS MARKET
  • 5.6.2 PRECISION MEDICINE MARKET
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PIPELINE ANALYSIS
• 5.9 DIAGNOSTIC PRODUCT ANALYSIS
• 5.10 INVESTMENT/FUNDING ACTIVITY
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Next-generation sequencing
    • 5.11.1.2 Immunohistochemistry
    • 5.11.1.3 Liquid biopsy
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Single-cell analysis
    • 5.11.2.2 AI and ML integration
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Theranostics
    • 5.11.3.2 Imaging technologies
• 5.12 PATENT ANALYSIS
• 5.13 TRADE ANALYSIS
  • 5.13.1 IMPORT DATA
  • 5.13.2 EXPORT DATA
• 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.15 REGULATORY LANDSCAPE
  • 5.15.1 REGULATORY ANALYSIS
    • 5.15.1.1 North America
    • 5.15.1.2 Europe
    • 5.15.1.3 Asia Pacific
    • 5.15.1.4 Rest of the World
  • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.16 PORTER'S FIVE FORCES ANALYSIS
  • 5.16.1 PRECISION DIAGNOSTICS MARKET
    • 5.16.1.1 Threat of new entrants
    • 5.16.1.2 Threat of substitutes
    • 5.16.1.3 Bargaining power of buyers
    • 5.16.1.4 Bargaining power of suppliers
    • 5.16.1.5 Intensity of competitive rivalry
  • 5.16.2 PRECISION MEDICINE MARKET
    • 5.16.2.1 Threat of new entrants
    • 5.16.2.2 Threat of substitutes
    • 5.16.2.3 Bargaining power of buyers
    • 5.16.2.4 Bargaining power of suppliers
    • 5.16.2.5 Intensity of competitive rivalry
• 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.17.2 BUYING CRITERIA
• 5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES
  • 5.18.3 AI USE CASES
  • 5.18.4 KEY COMPANIES IMPLEMENTING AI
  • 5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM

6 PRECISION DIAGNOSTICS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 GENETIC TESTING
  • 6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH
• 6.3 DTC TESTING
  • 6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH
• 6.4 OTHER TYPES

7 PRECISION DIAGNOSTICS MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 ONCOLOGY
  • 7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH
• 7.3 NEUROLOGY
  • 7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET
• 7.4 IMMUNOLOGY
  • 7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET
• 7.5 OTHER DIAGNOSTIC INDICATIONS

8 PRECISION DIAGNOSTICS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 CLINICAL LABORATORIES
  • 8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH
• 8.3 HOSPITALS
  • 8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET
• 8.4 HOME CARE SETTINGS
  • 8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH

9 PRECISION MEDICINE MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 MONOCLONAL ANTIBODIES
  • 9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH
• 9.3 INHIBITOR DRUGS
  • 9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH
• 9.4 CELL & GENE THERAPIES
  • 9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET
• 9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS
  • 9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH
• 9.6 OTHER PRODUCTS

10 PRECISION MEDICINE MARKET, BY INDICATION

• 10.1 INTRODUCTION
• 10.2 ONCOLOGY
  • 10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET
• 10.3 RARE DISEASES
  • 10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH
• 10.4 INFECTIOUS DISEASES
  • 10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET
• 10.5 HEMATOLOGICAL DISORDERS
  • 10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH
• 10.6 OTHER MEDICINE INDICATIONS

11 PRECISION MEDICINE MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITALS & CLINICS
  • 11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET
• 11.3 HOME CARE SETTINGS
  • 11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH

12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth
  • 12.2.3 CANADA
    • 12.2.3.1 Growing cancer burden to support growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market
  • 12.3.3 UK
    • 12.3.3.1 Favorable government support to expedite growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Growing preference for personalized medicine to fuel market
  • 12.3.5 ITALY
    • 12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.
  • 12.3.6 SPAIN
    • 12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Growing regulatory approvals for precision medicines to boost market
  • 12.4.3 JAPAN
    • 12.4.3.1 Increasing availability of health insurance to encourage growth
  • 12.4.4 INDIA
    • 12.4.4.1 Rising burden of chronic diseases to promote growth
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Booming research & development investments to spur growth
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Booming biopharmaceutical sector to contribute to growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024
  • 13.2.1 PRECISION DIAGNOSTICS MARKET
  • 13.2.2 PRECISION MEDICINE MARKET
• 13.3 REVENUE ANALYSIS, 2021-2023
  • 13.3.1 PRECISION DIAGNOSTICS MARKET
  • 13.3.2 PRECISION MEDICINE MARKET
• 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.4.1 PRECISION DIAGNOSTICS MARKET
  • 13.4.2 PRECISION MEDICINE MARKET
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 PRECISION DIAGNOSTICS MARKET
    • 13.5.1.1 Stars
    • 13.5.1.2 Emerging leaders
    • 13.5.1.3 Pervasive players
    • 13.5.1.4 Participants
    • 13.5.1.5 Company footprint: Key players, 2023
      • 13.5.1.5.1 Company footprint
      • 13.5.1.5.2 Region footprint
      • 13.5.1.5.3 Type footprint
      • 13.5.1.5.4 Indication footprint
  • 13.5.2 PRECISION MEDICINE MARKET
    • 13.5.2.1 Stars
    • 13.5.2.2 Emerging leaders
    • 13.5.2.3 Pervasive players
    • 13.5.2.4 Participants
    • 13.5.2.5 Company footprint: Key players, 2023
      • 13.5.2.5.1 Company footprint
      • 13.5.2.5.2 Region footprint
      • 13.5.2.5.3 Product footprint
      • 13.5.2.5.4 Indication footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PRECISION DIAGNOSTICS MARKET
    • 13.6.1.1 Progressive companies
    • 13.6.1.2 Responsive companies
    • 13.6.1.3 Dynamic companies
    • 13.6.1.4 Starting blocks
    • 13.6.1.5 Competitive benchmarking
      • 13.6.1.5.1 Detailed list of key startups/SMES
      • 13.6.1.5.2 Competitive benchmarking of startups/SMEs
  • 13.6.2 PRECISION MEDICINE MARKET
    • 13.6.2.1 Progressive companies
    • 13.6.2.2 Responsive companies
    • 13.6.2.3 Dynamic companies
    • 13.6.2.4 Starting blocks
    • 13.6.2.5 Competitive benchmarking
      • 13.6.2.5.1 Detailed list of key startups/SMES
      • 13.6.2.5.2 Competitive benchmarking of startups/SMEs
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 PRECISION DIAGNOSTICS MARKET
  • 13.7.2 PRECISION MEDICINE MARKET
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
• 13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches and approvals
      • 14.1.1.3.2 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 ABBOTT
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 AGILENT TECHNOLOGIES, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches and approvals
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 GUARDANT HEALTH
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches and approvals
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 EXACT SCIENCES CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 QIAGEN
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches and approvals
      • 14.1.6.3.2 Deals
  • 14.1.7 MYRIAD GENETICS, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches and approvals
      • 14.1.7.3.2 Deals
      • 14.1.7.3.3 Other developments
  • 14.1.8 NATERA, INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches and approvals
      • 14.1.8.3.2 Deals
  • 14.1.9 ILLUMINA, INC.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches and approvals
      • 14.1.9.3.2 Deals
  • 14.1.10 THERMO FISHER SCIENTIFIC INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
      • 14.1.10.3.2 Deals
  • 14.1.11 DANAHER
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches and approvals
      • 14.1.11.3.2 Deals
  • 14.1.12 23ANDME, INC.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 MERCK & CO., INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches and approvals
      • 14.1.13.3.2 Deals
  • 14.1.14 GILEAD SCIENCES, INC.
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches and approvals
      • 14.1.14.3.2 Deals
  • 14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Product launches and approvals
  • 14.1.16 BRISTOL-MYERS SQUIBB COMPANY
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Product launches and approvals
      • 14.1.16.3.2 Deals
  • 14.1.17 NOVARTIS AG
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Product launches and approvals
      • 14.1.17.3.2 Deals
  • 14.1.18 ASTRAZENECA
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products offered
    • 14.1.18.3 Recent developments
      • 14.1.18.3.1 Product launches and approvals
      • 14.1.18.3.2 Deals
  • 14.1.19 ABBVIE INC.
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products offered
    • 14.1.19.3 Recent developments
      • 14.1.19.3.1 Product launches and approvals
      • 14.1.19.3.2 Deals
      • 14.1.19.3.3 Expansions
  • 14.1.20 LILLY
    • 14.1.20.1 Business overview
    • 14.1.20.2 Products offered
    • 14.1.20.3 Recent developments
      • 14.1.20.3.1 Product launches and approvals
      • 14.1.20.3.2 Deals
  • 14.1.21 PFIZER INC.
    • 14.1.21.1 Business overview
    • 14.1.21.2 Products offered
    • 14.1.21.3 Recent developments
      • 14.1.21.3.1 Product launches and approvals
      • 14.1.21.3.2 Deals
  • 14.1.22 SAREPTA THERAPEUTICS, INC.
    • 14.1.22.1 Business overview
    • 14.1.22.2 Products offered
    • 14.1.22.3 Recent developments
      • 14.1.22.3.1 Product launches and approvals
      • 14.1.22.3.2 Deals
  • 14.1.23 VERTEX PHARMACEUTICALS INCORPORATED
    • 14.1.23.1 Business overview
    • 14.1.23.2 Products offered
    • 14.1.23.3 Recent developments
      • 14.1.23.3.1 Product launches and approvals
      • 14.1.23.3.2 Deals
  • 14.1.24 GSK PLC.
    • 14.1.24.1 Business overview
    • 14.1.24.2 Products offered
    • 14.1.24.3 Recent developments
      • 14.1.24.3.1 Product launches and approvals
      • 14.1.24.3.2 Deals
• 14.2 OTHER PLAYERS
  • 14.2.1 SANOFI
  • 14.2.2 JOHNSON & JOHNSON SERVICES, INC.
  • 14.2.3 AMGEN INC.
  • 14.2.4 MERCK KGAA
  • 14.2.5 ALNYLAM PHARMACEUTICALS, INC.
  • 14.2.6 INCYTE
  • 14.2.7 ARUP LABORATORIES
  • 14.2.8 DEVYSER
  • 14.2.9 DIASORIN S.P.A.
  • 14.2.10 TEMPUS
  • 14.2.11 PILLAR BIOSCIENCES INC.
  • 14.2.12 INVIVOSCRIBE, INC.
  • 14.2.13 NEUROCODE
  • 14.2.14 C2N DIAGNOSTICS
  • 14.2.15 TRINITY BIOTECH
  • 14.2.16 AMOY DIAGNOSTICS CO., LTD.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RISK ASSESSMENT
• TABLE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
• TABLE 4 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021-2023 (USD)
• TABLE 5 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER, 2021-2023 (USD)
• TABLE 6 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY REGION, 2021-2023 (USD)
• TABLE 7 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 8 PRECISION MEDICINE PRODUCTS IN CLINICAL PIPELINE, 2025-2029
• TABLE 9 PRECISION DIAGNOSTIC TESTS APPROVED BY FDA
• TABLE 10 PRECISION DIAGNOSTIC PRODUCTS ANALYSIS
• TABLE 11 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
• TABLE 12 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2019-2024
• TABLE 13 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (USD THOUSAND)
• TABLE 14 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (TONS)
• TABLE 15 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (USD THOUSAND)
• TABLE 16 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019-2023 (TONS)
• TABLE 17 PRECISION DIAGNOSTICS AND MEDICINE MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
• TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 22 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 23 PRECISION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 24 PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE
• TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT
• TABLE 27 BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER
• TABLE 28 BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER
• TABLE 29 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 30 PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022-2029 (USD BILLION)
• TABLE 31 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 32 EUROPE: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 33 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 34 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 35 PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY REGION, 2022-2029 (USD BILLION)
• TABLE 36 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 37 EUROPE: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 38 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 39 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 40 PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY REGION, 2022-2029 (USD BILLION)
• TABLE 41 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 42 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 43 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 44 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 45 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 46 PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD BILLION)
• TABLE 47 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 48 EUROPE: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 49 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 50 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 51 PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY REGION, 2022-2029 (USD BILLION)
• TABLE 52 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 53 EUROPE: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 54 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 55 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 56 PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY REGION, 2022-2029 (USD BILLION)
• TABLE 57 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 58 EUROPE: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 59 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 60 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 61 PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 62 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 63 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 64 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 65 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 66 PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 67 PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD BILLION)
• TABLE 68 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 69 EUROPE: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 70 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 71 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 72 PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 73 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 74 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 75 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 76 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 77 PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 78 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 79 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 80 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 81 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 82 PRECISION MEDICINE MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 83 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2029 (USD BILLION)
• TABLE 84 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 85 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 86 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 87 LATIN AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 88 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 89 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 90 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 91 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 92 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 93 PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY REGION, 2022-2029 (USD BILLION)
• TABLE 94 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 95 EUROPE: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 96 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 97 LATIN AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 98 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 99 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 100 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 102 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 103 PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 104 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 105 EUROPE: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 106 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 107 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 108 PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 109 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD BILLION)
• TABLE 110 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 111 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 112 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 113 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 114 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2022-2029 (USD BILLION)
• TABLE 115 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 116 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 117 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 118 LATIN AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 119 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD BILLION)
• TABLE 120 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 121 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 122 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 123 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 124 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 125 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 126 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 127 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 128 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 129 PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY REGION, 2022-2029 (USD BILLION)
• TABLE 130 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 131 EUROPE: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 132 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 133 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 134 PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 135 PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 136 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 137 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 138 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 139 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 140 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 141 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 142 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 143 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 144 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 145 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION, 2022-2029 (USD BILLION)
• TABLE 146 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 147 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 148 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 149 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 150 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 151 NORTH AMERICA: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 152 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 153 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 155 US: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 156 US: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 157 US: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 158 US: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 159 US: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 160 US: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 161 CANADA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 162 CANADA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 163 CANADA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 164 CANADA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 165 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 166 CANADA: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 167 EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 168 EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 169 EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 170 EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 171 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 172 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 173 EUROPE: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 174 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 175 EUROPE: KEY MACROECONOMIC INDICATORS
• TABLE 176 GERMANY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 177 GERMANY: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 178 GERMANY: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 179 GERMANY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 180 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 181 GERMANY: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 182 UK: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 183 UK: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 184 UK: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 185 UK: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 186 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 187 UK: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 188 FRANCE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 189 FRANCE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 190 FRANCE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 191 FRANCE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 192 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 193 FRANCE: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 194 ITALY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 195 ITALY: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 196 ITALY: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 197 ITALY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 198 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 199 ITALY: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 200 SPAIN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 201 SPAIN: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 202 SPAIN: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 203 SPAIN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 204 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 205 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 206 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 207 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 208 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 209 REST OF EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 210 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 211 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 212 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 213 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 214 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 215 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 216 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 217 ASIA PACIFIC: PRECISION MEDICINE MARKET, END USER, 2022-2029 (USD BILLION)
• TABLE 218 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 219 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 220 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
• TABLE 221 CHINA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 222 CHINA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 223 CHINA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 224 CHINA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 225 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 226 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 227 JAPAN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 228 JAPAN: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 229 JAPAN: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 230 JAPAN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 231 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 232 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 233 INDIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 234 INDIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 235 INDIA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 236 INDIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 237 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 238 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 239 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 240 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 241 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 242 AUSTRALIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 243 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 244 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 245 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 246 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 247 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 248 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 249 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 250 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 251 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 252 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 253 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 254 LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 255 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 256 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 257 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 258 LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
• TABLE 259 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 260 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 261 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 262 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 263 BRAZIL: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 264 BRAZIL: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 265 BRAZIL: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 266 MEXICO: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 267 MEXICO: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 268 MEXICO: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 269 MEXICO: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 270 MEXICO: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 271 MEXICO: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 272 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 273 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 274 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 275 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 276 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 277 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 278 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022-2029 (USD BILLION)
• TABLE 279 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 280 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 281 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022-2029 (USD BILLION)
• TABLE 282 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022-2029 (USD BILLION)
• TABLE 283 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2022-2029 (USD BILLION)
• TABLE 284 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
• TABLE 285 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION DIAGNOSTICS MARKET, JANUARY 2021-NOVEMBER 2024
• TABLE 286 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION MEDICINE MARKET, JANUARY 2021-NOVEMBER 2024
• TABLE 287 PRECISION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
• TABLE 288 PRECISION MEDICINE MARKET: DEGREE OF COMPETITION
• TABLE 289 PRECISION DIAGNOSTICS MARKET: REGION FOOTPRINT
• TABLE 290 PRECISION DIAGNOSTICS MARKET: TYPE FOOTPRINT
• TABLE 291 PRECISION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
• TABLE 292 PRECISION MEDICINE MARKET: REGION FOOTPRINT
• TABLE 293 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT
• TABLE 294 PRECISION MEDICINE MARKET: INDICATION FOOTPRINT
• TABLE 295 PRECISION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 296 PRECISION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 297 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 298 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 299 PRECISION DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 300 PRECISION DIAGNOSTICS MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 301 PRECISION DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
• TABLE 302 PRECISION MEDICINE MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 303 PRECISION MEDICINE MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 304 PRECISION MEDICINE: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
• TABLE 305 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY OVERVIEW
• TABLE 306 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCTS OFFERED
• TABLE 307 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 308 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 309 ABBOTT: COMPANY OVERVIEW
• TABLE 310 ABBOTT: PRODUCTS OFFERED
• TABLE 311 ABBOTT: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 312 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 313 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
• TABLE 314 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 315 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 316 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
• TABLE 317 GUARDANT HEALTH: COMPANY OVERVIEW
• TABLE 318 GUARDANT HEALTH: PRODUCTS OFFERED
• TABLE 319 GUARDANT HEALTH: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 320 GUARDANT HEALTH: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 321 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
• TABLE 322 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED
• TABLE 323 EXACT SCIENCES CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 324 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 325 QIAGEN: COMPANY OVERVIEW
• TABLE 326 QIAGEN: PRODUCTS OFFERED
• TABLE 327 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 328 QIAGEN: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 329 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
• TABLE 330 MYRIAD GENETICS, INC.: PRODUCTS OFFERED
• TABLE 331 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 332 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 333 MYRIAD GENETICS, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
• TABLE 334 NATERA, INC.: COMPANY OVERVIEW
• TABLE 335 NATERA, INC.: PRODUCTS OFFERED
• TABLE 336 NATERA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 337 NATERA, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 338 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 339 ILLUMINA, INC.: PRODUCTS OFFERED
• TABLE 340 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 341 ILLUMINA, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 342 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 343 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
• TABLE 344 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 345 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 346 DANAHER: COMPANY OVERVIEW
• TABLE 347 DANAHER: PRODUCTS OFFERED
• TABLE 348 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 349 DANAHER: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 350 23ANDME, INC.: COMPANY OVERVIEW
• TABLE 351 23ANDME, INC.: PRODUCTS OFFERED
• TABLE 352 23ANDME, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 353 MERCK & CO., INC.: COMPANY OVERVIEW
• TABLE 354 MERCK & CO., INC.: PRODUCTS OFFERED
• TABLE 355 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
• TABLE 356 MERCK & CO., INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 357 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
• TABLE 358 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
• TABLE 359 GILEAD SCIENCES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 360 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 361 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY OVERVIEW
• TABLE 362 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCTS OFFERED
• TABLE 363 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 364 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
• TABLE 365 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
• TABLE 366 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 367 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 368 NOVARTIS AG: COMPANY OVERVIEW
• TABLE 369 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 370 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 371 NOVARTIS AG: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 372 ASTRAZENECA: COMPANY OVERVIEW
• TABLE 373 ASTRAZENECA: PRODUCTS OFFERED
• TABLE 374 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 375 ASTRAZENECA: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 376 ABBVIE INC.: COMPANY OVERVIEW
• TABLE 377 ABBVIE INC.: PRODUCTS OFFERED
• TABLE 378 ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 379 ABBVIE INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 380 ABBVIE INC.: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
• TABLE 381 LILLY: COMPANY OVERVIEW
• TABLE 382 LILLY: PRODUCTS OFFERED
• TABLE 383 LILLY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 384 LILLY: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 385 PFIZER INC.: COMPANY OVERVIEW
• TABLE 386 PFIZER INC.: PRODUCTS OFFERED
• TABLE 387 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 388 PFIZER INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 389 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
• TABLE 390 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
• TABLE 391 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 392 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 393 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY OVERVIEW
• TABLE 394 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS OFFERED
• TABLE 395 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 396 VERTEX PHARMACEUTICALS INCORPORATED: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 397 GSK PLC.: COMPANY OVERVIEW
• TABLE 398 GSK PLC.: PRODUCTS OFFERED
• TABLE 399 GSK PLC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-NOVEMBER 2024
• TABLE 400 GSK PLC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 401 SANOFI: COMPANY OVERVIEW
• TABLE 402 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
• TABLE 403 AMGEN INC.: COMPANY OVERVIEW
• TABLE 404 MERCK KGAA: COMPANY OVERVIEW
• TABLE 405 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
• TABLE 406 INCYTE: COMPANY OVERVIEW
• TABLE 407 ARUP LABORATORIES: COMPANY OVERVIEW
• TABLE 408 DEVYSER: COMPANY OVERVIEW
• TABLE 409 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 410 TEMPUS: COMPANY OVERVIEW
• TABLE 411 PILLAR BIOSCIENCES INC.: COMPANY OVERVIEW
• TABLE 412 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
• TABLE 413 NEUROCODE: COMPANY OVERVIEW
• TABLE 414 C2N DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 415 TRINITY BIOTECH: COMPANY OVERVIEW
• TABLE 416 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET SEGMENTATION
• FIGURE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RESEARCH DESIGN
• FIGURE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
• FIGURE 4 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
• FIGURE 5 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE ANALYSIS, 2023
• FIGURE 7 PRECISION MEDICINE MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
• FIGURE 8 PRECISION MEDICINE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 9 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS, 2023
• FIGURE 10 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• FIGURE 11 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 12 PRECISION MEDICINE MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 13 PRECISION DIAGNOSTICS MARKET: CAGR PROJECTIONS, 2024-2029
• FIGURE 14 PRECISION MEDICINE MARKET: CAGR PROJECTIONS, 2024-2029
• FIGURE 15 PRECISION DIAGNOSTICS AND MEDICINE MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
• FIGURE 16 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DATA TRIANGULATION
• FIGURE 17 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
• FIGURE 18 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION)
• FIGURE 19 PRECISION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
• FIGURE 20 PRECISION MEDICINE MARKET, BY PRODUCT, 2024 VS. 2029 (USD BILLION)
• FIGURE 21 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION)
• FIGURE 22 PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
• FIGURE 23 GEOGRAPHICAL SNAPSHOT OF PRECISION DIAGNOSTICS MARKET, 2024-2029
• FIGURE 24 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET, 2024-2029
• FIGURE 25 INCREASING DEMAND FOR QUICK AND ACCURATE DIAGNOSTIC TESTS TO DRIVE PRECISION DIAGNOSTICS MARKET
• FIGURE 26 INCREASING NUMBER OF REGULATORY APPROVALS FOR PERSONALIZED MEDICINES TO DRIVE PRECISION MEDICINE MARKET
• FIGURE 27 GENETIC TESTING SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF PRECISION DIAGNOSTICS MARKET IN 2023
• FIGURE 28 ONCOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD
• FIGURE 29 HOME CARE SETTINGS MARKET COMMANDED HIGHEST SHARE IN 2023
• FIGURE 30 MONOCLONAL ANTIBODIES AND US LED NORTH AMERICAN PRECISION MEDICINE MARKET IN 2023
• FIGURE 31 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 32 JAPAN TO REGISTER HIGHEST GROWTH IN PRECISION DIAGNOSTICS MARKET DURING FORECAST PERIOD
• FIGURE 33 GERMANY TO REGISTER HIGHEST GROWTH IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD
• FIGURE 34 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 35 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PRECISION DIAGNOSTICS AND MEDICINE MARKET
• FIGURE 36 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021-2023 (USD)
• FIGURE 37 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER, 2021-2023 (USD)
• FIGURE 38 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY REGION, 2021-2023 (USD)
• FIGURE 39 PRECISION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 40 PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS
• FIGURE 41 PRECISION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 42 PRECISION MEDICINE MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 43 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ECOSYSTEM ANALYSIS
• FIGURE 44 PRECISION DIAGNOSTICS AND MEDICINE MARKET: PATENT ANALYSIS, JANUARY 2014-NOVEMBER 2024
• FIGURE 45 PRECISION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 46 PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 47 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE
• FIGURE 48 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT
• FIGURE 49 KEY BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER
• FIGURE 50 KEY BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER
• FIGURE 51 NORTH AMERICA: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT
• FIGURE 52 EUROPE: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT
• FIGURE 53 PRECISION DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
• FIGURE 54 PRECISION MEDICINE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
• FIGURE 55 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
• FIGURE 56 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
• FIGURE 57 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 58 PRECISION DIAGNOSTICS MARKET: COMPANY FOOTPRINT
• FIGURE 59 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 60 PRECISION MEDICINE MARKET: COMPANY FOOTPRINT
• FIGURE 61 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 62 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 63 PRECISION DIAGNOSTICS MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
• FIGURE 64 PRECISION DIAGNOSTICS MARKET: EV/EBITDA OF KEY VENDORS, 2024
• FIGURE 65 PRECISION MEDICINE MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
• FIGURE 66 PRECISION MEDICINE MARKET: EV/EBITDA OF KEY VENDORS, 2024
• FIGURE 67 PRECISION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 68 PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 69 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY SNAPSHOT (2023)
• FIGURE 70 ABBOTT: COMPANY SNAPSHOT (2023)
• FIGURE 71 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 72 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
• FIGURE 73 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023)
• FIGURE 74 QIAGEN: COMPANY SNAPSHOT (2023)
• FIGURE 75 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 76 NATERA, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 77 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 78 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
• FIGURE 79 DANAHER: COMPANY SNAPSHOT (2023)
• FIGURE 80 23ANDME, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 81 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
• FIGURE 82 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 83 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY SNAPSHOT (2023)
• FIGURE 84 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
• FIGURE 85 NOVARTIS AG: COMPANY SNAPSHOT (2023)
• FIGURE 86 ASTRAZENECA: COMPANY SNAPSHOT (2023)
• FIGURE 87 ABBVIE INC.: COMPANY SNAPSHOT (2023)
• FIGURE 88 LILLY: COMPANY SNAPSHOT (2023)
• FIGURE 89 PFIZER INC.: COMPANY SNAPSHOT (2023)
• FIGURE 90 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 91 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT (2023)
• FIGURE 92 GSK PLC.: COMPANY SNAPSHOT (2023)